Previous research has indicated that patients with IDH wild‐type GBM usually have a poor prognosis compared to other glioma subtypes.[26] Therefore, we further verified the prognostic stratification ability of the IGLoS signature in IDH wild‐type GBM patients. The gene discussed is IDH2; the disease is central nervous system cancer.